Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DX-DRG-M01
- Development stage
- Preclinical
- Lead developer
- Dx&Vx
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
01
Overview
DX-DRG-M01 is an early-stage microbiome-based bacterial vaccine candidate being developed by Dx&Vx (formerly MG Med) for the prevention or treatment of infectious diseases. The vaccine utilizes a microbiome-derived bacterial platform intended to elicit a targeted immune response against pathogens. As of early 2024, the program is in the discovery or preclinical stage of development. While the specific target pathogens and detailed molecular mechanism of action have not been publicly disclosed, the asset represents Dx&Vx's strategic focus on leveraging microbiome technology for next-generation therapeutic and prophylactic applications in the infectious disease space.
- Other names
- Microbiome Bacteria Vaccine마이크로바이옴 박테리아 백신
02
Targets
CLDN5 (Claudin-5)
Beyond the preview
Go deeper on DX-DRG-M01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DX-DRG-M01.